1.Adherence to atorvastatin therapy in coronary prevention evaluated by drug plasma concentrations. Kristiansen O. et al., Br J Clin Pharmacol. 2019;1–8.
2.Statin-associated muscle symptoms in coronary patients: design of a randomized study. Munkhaugen J. et al., Scand Cardiovasc J. 2019 Jun.
3.Medical and Psychosocial Factors Associated With Low Physical Activity and Increasing Exercise Level After a Coronary Event. Peersen K. et al., J Cardiopulm Rehabil Prev. 2019 Jan 31.
4.A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. Vethe NT. et al., Ther Drug Monit. 2019 Feb.
5.OPPFØLGING ETTER HJERTEINFARKT – ER DEN GOD NOK? Munkhaugen J., Referat av foredrag på Norsk Cardiologisk Selskaps Høstmøte hjerteforum 27.-29.11.2018 publisert i Hjerteforum N° 1/ 2019 / vol 32
6.The prevalence of mental disorders in patients with coronary heart disease and type D personality. Dammen T. et al., Eur J Prev Cardiol. June 12, 2019 (Poster, EuroPRevent 2018, Lisboa)
7.Prevalence and correlates of insomnia in coronary heart disease patients. Aastebøl Frøjd L. et al., Eur J Prev Cardiol. June 12, 2019 (Poster, EuroPRevent 2018, Lisboa)
8.Adherence to atorvastatin therapy in coronary prevention evaluated by drug plasma concentrations. Kristiansen O. et al., Eur J Prev Cardiol. June 12, 2019 (Poster, EuroPRevent 2018, Lisboa).
9.Betablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Munkhaugen J. et al., Am Heart J. 2019 Feb.
10.Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Dahl Aarvik M. et al., Eur Heart J Cardiovasc Pharmacother. 2019 Jan.